A Phase I Study of STA-5312 Administered Weekly in Subjects With Advanced or Metastatic Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 31 Jan 2014
At a glance
- Drugs Rosabulin (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Synta Pharmaceuticals
- 31 Jan 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 03 Feb 2006 New trial record.